AbbVie

Q3 2026
Speakers

Oct 30, 2026 · 77 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Good morning and thank you for standing by. Welcome to the Abbey Third Quarter 2026 Earnings Conference Call. All participants will be able to listen only until the question and answer portion of this call. You may ask a question by pressing star one on your phone. Today's call is also being recorded. If you have any objections, you may disconnect at this time. ?I would now like to introduce Ms.

Liz Shea, Senior Vice President, Investor Relations.

Passages & reports (4)
  • Good morning and thank you for standing by. Welcome to the Abbey Third Quarter 2026 Earnin…
  • have any objections, you may disconnect at this time.
  • I
  • would now like to introduce Ms. Liz Shea, Senior Vice President, Investor Relations.

Good

Passages & reports (1)
  • Good

Speaker 1

Unverified voice label

morning, and thanks

Passages & reports (1)
  • morning, and thanks

Speaker 0

for joining us. Also on the call with me today are Rob Michael, Chairman and Chief Executive Officer, Jeff Stewart, Executive Vice President, Chief Commercial Officer, Rupal Thacker, Executive Vice President, ?Research and Development, Chief Scientific Officer, and Scott Rentz, Executive ?Vice President, Chief Financial Officer.

Passages & reports (5)
  • for joining us. Also on the call with me today are Rob Michael, Chairman and Chief Executi…
  • Research and Development,
  • Chief Scientific Officer, and Scott Rentz, Executive
  • Vice President, Chief Financial
  • Officer.

Speaker 1

Before

Passages & reports (1)
  • Before

Speaker unclear

?we get started, I'll note that

Passages & reports (1)
  • we get started, I'll note that

Speaker 1

some statements we ?make today may be considered forward-looking statements based on our current expectations. Abby cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. ABVI undertakes no obligation to update these forward-looking statements except as required by law. ?

On
today's conference call, non-GAAP financial measures will be used to help investors understand ABVI's business performance. These non-GAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we'll take your questions. So with that, I'll turn the call over to Rob.

Passages & reports (7)
  • some statements we
  • make
  • today may be considered forward-looking statements based on our current expectations. Abby…
  • obligation to update these forward-looking statements except as required by law.
  • On
  • today's conference call, non-GAAP financial measures will be used to help investors unders…
  • turn the call over to Rob.

Speaker 2

Unverified voice label

Thank you, Liz. Good morning everyone, and thank you for joining us. ABVI continues to perform above our expectations with another quarter of outstanding results. We are delivering top-tier sales and earnings growth and making significant progress advancing our pipeline. Given the strength of our business and our promising outlook, we are once again raising our full year guidance and increasing our quarterly dividend.

Passages & reports (2)
  • Thank you, Liz. Good morning everyone, and thank you for joining us. ABVI continues to per…
  • pipeline. Given the strength of our business and our promising outlook, we are once again …

Turning to our third quarter performance, we achieved adjusted earnings per share of $3.82, which is 7 cents above our guidance midpoint. Total net revenues were $17.4 billion, beating our expectations by $200 million and reflecting robust sales growth of more than 10%. This includes nine key products that delivered double-digit growth. Based on the strong performance across our business, including SkyRizi, Rinvoke, Vrailar, Ubrelvi, Culypta, and Ben Clexta, we are raising our full year revenue guidance by $200 million and have now raised total revenue by $800 million since the start of the year.

Further underscoring our confidence in our long-term outlook, today we announced a 5.2% increase in our quarterly cash
dividend, beginning with the dividend payable in February 2027. Since inception, we have grown our quarterly dividend by more than 350%.

Passages & reports (4)
  • Turning to our third quarter performance, we achieved adjusted earnings per share of $3.82…
  • robust sales growth of more than 10%. This includes nine key products that delivered doubl…
  • raising our full year revenue guidance by $200 million and have now raised total revenue b…
  • dividend, beginning with the dividend payable in February 2027. Since inception, we have g…

Speaker 2

Turning now to RD, we are making excellent progress advancing our pipeline to help drive growth in the 2030s and beyond. In immunology, we completed the acquisition of apogee therapeutics, adding multiple differentiated assets in dermatology, respiratory, and other related inflammatory diseases with significant sales potential. ?The lead asset, Zumi LokiBart, will be starting phase three development in atopic dermatitis later this year. Also in immunology, we received U.S.

approval for SkyRISI sub Q induction in Crohn's. This new dosing option demonstrated exceptional efficacy and
further strengthens SkyRISI's robust growth outlook. We also continue to make substantial progress with our strategy to combine SkyRISI with complementary mechanisms to further elevate the standard of care for patients with IBD. We have now started a large Phase 2B program in both Crohn's and UC with SkyRISI plus our Alpha 4 Beta 7 382 as well as SkyRISI plus our TL1A 701.

Moving to neuroscience, we recently expanded our Parkinson's portfolio
with the FDA approval of Juvmo. Juvmo provides physicians and patients with a meaningful new treatment option and represents a sizable commercial opportunity for ABVI. Along with Vialevin Duopa, we expect our Parkinson's therapies to collectively deliver peak sales of more than $5 billion. We are also making excellent progress with our oncology pipeline. EtensamIG and multiple myeloma has demonstrated very high efficacy as well as differentiated safety and convenience.

We have now submitted our application for a
Tentamig in the U.S. and anticipate approval in 2027. In addition, we reported positive phase three data for Epkinley and frontline DLBCL and expect regulatory submission next year. In summary, we are delivering strong execution across our business and see numerous opportunities to drive long-term growth. With that, I'll turn the call over to Jeff for additional comments on our commercial highlights.

Jeff? Thank you, Rob. I'll start with

Passages & reports (10)
  • Turning now to RD, we are making excellent progress advancing our pipeline to help drive g…
  • respiratory, and other related inflammatory diseases with significant sales potential.
  • The
  • lead asset, Zumi LokiBart, will be starting phase three development in atopic dermatitis l…
  • further strengthens SkyRISI's robust growth outlook. We also continue to make substantial …
  • 2B program in both Crohn's and UC with SkyRISI plus our Alpha 4 Beta 7 382 as well as SkyR…
  • with the FDA approval of Juvmo. Juvmo provides physicians and patients with a meaningful n…
  • sales of more than $5 billion. We are also making excellent progress with our oncology pip…
  • Tentamig in the U.S. and anticipate approval in 2027. In addition, we reported positive ph…
  • execution across our business and see numerous opportunities to drive long-term growth. Wi…

Speaker unclear

?the quarterly

Passages & reports (1)
  • the quarterly

Speaker 3

Unverified voice label

results for immunology, which delivered total revenues approaching $9.2 billion, reflecting operational sales growth of 16.6%. SkyRizi and Rinvo continue to exceed our expectations, demonstrating robust growth across all indications. SkyRizi total sales were nearly $5.8 billion, up 22.9% on an operational basis. In psoriasis, Skyrisi prescription trends remain very strong. Recent oral competition is not having a substantive impact on our in-play patient share, ?with Skyrisi continuing to capture roughly one out of every two new or switching psoriasis patients. ?

We
believe that SkyRISI is best in class profile, which delivers 100% skin clearance for the majority of psoriasis patients, high durability of response, very convenient quarterly dosing, exceptional long-term safety, and robust joint protection in psoriatic arthritis with strong data through five years of treatment sets a very high bar relative to other therapies on the market or in development for psoriasis. ?In IBD, Skyrisi is growing very robustly as well and continues to capture half ?of the new patient starts in the class. ?

And
we are very excited to be launching the subcutaneous induction dosing for Crohn's disease, which further strengthens our competitive position. The data supporting this new delivery is striking, including impressive rates of endoscopic response and remission, particularly for CD patients in the frontline setting. This efficacy is clearly differentiated relative to our own SkyRISI IV formulation and will allow us to be very competitive versus all induction therapies available for Crohn's today.

Our sub Q induction regimen is delivered with the same on body injector as our IBD maintenance dose, which has received very
favorable feedback from gastroenterologists and patients both, including overall ease of use, dosing speed, and comfort. ?Now, while access typically takes a couple months to ramp, our commercial and medical teams have already hit the ground running, and we expect the sub Q induction will accelerate our new patient share in Crohn's over the next several quarters.

Overall, we remain very competitively positioned in gastro and psoriatic disease.
?We are raising our SkyRISI full-year sales guidance for the third time this year, and we see a substantial opportunity for both market and share growth well into the next decade. Turning now to RinVoke, which delivered global sales of $2.7 billion, reflecting operational growth of 24.3%. Rinvoke is also exceeding our expectations with particularly strong momentum in both RA and IBD, where we continue to see growing in-play patient share.

We are also excited for the indication expansion opportunities in dermatology, with commercialization of Rinvolk for vitiligo and alopecia ariata underway already
in Europe, and approvals expected ?for both diseases in the U.S. over the next several months. Recall these two new indications combined are expected to contribute nearly $2 billion of peak sales. Lastly, in immunology, Humera Global Sales were $683 million down 30.6% on an operational basis, reflecting continued biosimilar competition.

Moving to neuroscience, where we continue to outperform expectations across our leading portfolio, total revenues were nearly $3.4 billion up 19.5% on an operational basis. In psychiatry, Vraylar Global Sales were nearly $1.1 billion
up 14.3%. Performance in both bipolar disorder and adjunctive MDD continues to be very strong, reflecting Vraylar's well-defined profile in terms of dosing flexibility, low sedation, and the ability to treat a full spectrum of symptoms.

In migraine, we continued to deliver
robust sales growth driven by share gains and underlying market growth as well. Botox therapeutic global revenues were approximately $1.1 billion, up 9.8%. Ubrelvi global sales were $449 million, up 26.9%, and QLIPTA global revenues were $398 million, up more than 38%. Menstrual migraine prevention represents another opportunity to further strengthen our leading CGRP profiles. Recent positive data for Clipta and forthcoming results for Ubrelvi in this new potential indication could support approval and commercialization in late 2027.

Passages & reports (28)
  • results for immunology, which delivered total revenues approaching $9.2 billion, reflectin…
  • up 22.9% on an operational basis. In psoriasis, Skyrisi prescription trends remain very st…
  • with
  • Skyrisi continuing to capture roughly one out of every two new or switching psoriasis pati…
  • We
  • believe that SkyRISI is best in class profile, which delivers 100% skin clearance for the …
  • sets a very high bar relative to other therapies on the market or in development for psori…
  • In
  • IBD, Skyrisi is growing very robustly as well and continues to capture half
  • of
  • the new patient starts in the class.
  • And
  • we are very excited to be launching the subcutaneous induction dosing for Crohn's disease,…
  • efficacy is clearly differentiated relative to our own SkyRISI IV formulation and will all…
  • favorable feedback from gastroenterologists and patients both, including overall ease of u…
  • Now,
  • while access typically takes a couple months to ramp, our commercial and medical teams hav…
  • We
  • are raising our SkyRISI full-year sales guidance for the third time this year, and we see …
  • exceeding our expectations with particularly strong momentum in both RA and IBD, where we …
  • in Europe, and approvals expected
  • for
  • both diseases in the U.S. over the next several months. Recall these two new indications c…
  • biosimilar competition. Moving to neuroscience, where we continue to outperform expectatio…
  • up 14.3%. Performance in both bipolar disorder and adjunctive MDD continues to be very str…
  • robust sales growth driven by share gains and underlying market growth as well. Botox ther…
  • $398 million, up more than 38%. Menstrual migraine prevention represents another opportuni…
  • commercialization in late 2027.

Speaker 3

Violeb total sales were $286 million, reflecting double digit growth. We remain on track to exceed $1 billion in revenue this year. We are also launching Juvmo, another exciting new treatment for patients with Parkinson's. Juvmo selectively activates the D1 D5 dopamine receptors involved in motor control and can be prescribed now as both a monotherapy in Parkinson's as well as an add-on to standard of care. ?

And
given JuveMO's distinct profile, including strong durable motor control and low rates of debilitating side effects, such as impulse control disorder, somnolence, and dykinesia, it represents a sizable commercial opportunity. ?Sales for JUM are expected to ramp gradually over the next several quarters as we work to establish commercial and Medicare coverage, which is expected to be more broadly available starting in 2028. Turning now to oncology, where total revenues were $1.7 billion, up 0.9% on an operational basis.

Vanclex is performing very well, especially in CLL as combination use with BTK inhibitors is a preferred fixed duration treatment globally. Total sales were $803 million up 10.7%. Continued double-digit sales growth from Ellahir and Epkinley also helped to
offset the expected revenue decline for Imbruvica, which was down 26.1% due to IRA pricing and competitive share pressure. I'm also very excited for our developing portfolio in hematology following positive data for both in Tentamig and Multiple Myeloma and at Kinley in frontline DLBCL.

We anticipate their potential approvals will be an important catalyst for next year and immediately supported by our existing commercial resources, including a substantial HEME Salesforce and Medical Affairs team. Lastly in aesthetics, global sales were nearly $1.2 billion
down 1.8% on an operational basis. Botox cosmetic total revenues were $669 million up 4.1% operationally, reflecting improving market growth globally. Juvederm global sales were $222 million down 11.8% operationally, reflecting continued headwinds in key dermal filler markets.

While economic uncertainty and lower consumer confidence have pressured the aesthetics category over the last several quarters, we are starting to see signs of stability.
?And we think that bringing forward innovation, like our new fast-acting short-duration toxin Bowie, represents a meaningful opportunity for more new patients to initiate an aesthetic treatment. The commercial rollout of Bowie is now underway in Europe and Canada, and patient satisfaction has been very high, particularly with the rapid onset, which is consistent with the data from our clinical program.

So overall, I'm very pleased with the execution and the continued strong performance across our commercial portfolio.
?And now I'll turn the call over to RuPaul for comments on our RD highlights. Ruppel? Thank you, Jeff. I'll begin with gastroenterology

Passages & reports (16)
  • Violeb total sales were $286 million, reflecting double digit growth. We remain on track t…
  • receptors involved in motor control and can be prescribed now as both a monotherapy in Par…
  • And
  • given JuveMO's distinct profile, including strong durable motor control and low rates of d…
  • Sales
  • for JUM are expected to ramp gradually over the next several quarters as we work to establ…
  • Vanclex is performing very well, especially in CLL as combination use with BTK inhibitors …
  • offset the expected revenue decline for Imbruvica, which was down 26.1% due to IRA pricing…
  • DLBCL. We anticipate their potential approvals will be an important catalyst for next year…
  • down 1.8% on an operational basis. Botox cosmetic total revenues were $669 million up 4.1%…
  • filler markets. While economic uncertainty and lower consumer confidence have pressured th…
  • And
  • we think that bringing forward innovation, like our new fast-acting short-duration toxin B…
  • onset, which is consistent with the data from our clinical program. So overall, I'm very p…
  • And
  • now I'll turn the call over to RuPaul for comments on our RD highlights. Ruppel? Thank you…

Speaker 2

programs in immunology.

Passages & reports (1)
  • programs in immunology.

Speaker 3

We

Passages & reports (1)
  • We

Speaker 2

further strengthened our leadership position in inflammatory bowel disease with the FDA approval ?of Skyrisi subcutaneous induction in Crohn's disease, which was based on the phase three affirmed study. Detailed results from this trial were presented at the recent ACG and UEG meetings, demonstrating exceptional results across all clinical and endoscopic measures. We are extremely pleased with Skyrizi's strong performance, particularly in patients who had not previously experienced advanced therapy. ?

In
this patient segment, unprecedented results were observed after just 16 weeks of therapy, with 60% endoscopic response, 43% endoscopic remission, and 74% for clinical remission. These results highlight the potential of subcutaneous induction to further enhance Skyrisi's position in earlier lines of Crohn's disease. Additionally, the SkyRISI label was updated to provide healthcare providers greater discretion in determining whether tuberculosis evaluation is appropriate prior to treatment initiation, rather than requiring mandatory TB evaluation for all patients.

Also, at the UEG conference, results were presented from the phase two target CD study evaluating Skyrisi plus our novel anti-alpha-4 beta 7
antibody, ABB382, in Crohn's disease. The combination resulted in a near doubling of endoscopic remission at week 24 compared to either monotherapy. Additionally, gut gene expression data showed a clear improvement from active disease at baseline to early intestinal healing at week twelve, followed by broader tissue restoration at week twenty four.

Early changes reflected repair of the intestinal lining and restoration of the gut barrier, effects not observed with monotherapy. By week twenty-four,
these changes evolved into signatures associated with tissue repair, nerve recovery, and normalization of metabolic function. We believe this progression from inflammation to healing and ultimately tissue restoration may represent an important step toward modifying the underlying disease rather than simply controlling symptoms.

These results support our strategy of combining skyrisi with complementary mechanisms to achieve meaningfully higher levels of efficacy in IBD. A large multi-arm phase two B trial is underway evaluating
SkyRIZI Plus 382 and SkyRIZI Plus 701, an extended half-life anti-TL1A antibody in both Crohn's disease and ulcerative colitis. In parallel, coformulation work is ongoing in preparation for phase three trials.

Passages & reports (13)
  • further strengthened our leadership position in inflammatory bowel disease with the FDA ap…
  • of
  • Skyrisi subcutaneous induction in Crohn's disease, which was based on the phase three affi…
  • extremely pleased with Skyrizi's strong performance, particularly in patients who had not …
  • In
  • this patient segment, unprecedented results were observed after just 16 weeks of therapy, …
  • subcutaneous induction to further enhance Skyrisi's position in earlier lines of Crohn's d…
  • to treatment initiation, rather than requiring mandatory TB evaluation for all patients. A…
  • antibody, ABB382, in Crohn's disease. The combination resulted in a near doubling of endos…
  • baseline to early intestinal healing at week twelve, followed by broader tissue restoratio…
  • these changes evolved into signatures associated with tissue repair, nerve recovery, and n…
  • disease rather than simply controlling symptoms. These results support our strategy of com…
  • SkyRIZI Plus 382 and SkyRIZI Plus 701, an extended half-life anti-TL1A antibody in both Cr…

Moving to dermatology, positive top-line results were recently announced from a phase three study evaluating ludicissimab in hydradnitis suprativa. At week 16, ludicizimab demonstrated statistically significant and clinically meaningful improvements across multiple measures of disease activity. High score 75, which is a rigorous bar for defining clinical response, was achieved by 31% of ludicizimab patients. Ludicissimab also significantly improves skin pain, disease flares, and quality of life measures, with improvement in pain reported as early as week one.

HS remains one of the most underserved diseases in dermatology, and these results support Ludicimab's potential to become an important new treatment option for patients with HS. Results from the 36-week blinded extension period
will be available next year, with regulatory submissions to follow in the second half of 2027. Based on these results, we plan to begin an HS platform study later this year to evaluate Ludicissimab in combination with our long-acting AMILINA Analog 295.

Other mechanisms such as anti-TL1A antibody are also being considered.

Passages & reports (5)
  • Moving to dermatology, positive top-line results were recently announced from a phase thre…
  • disease activity. High score 75, which is a rigorous bar for defining clinical response, w…
  • reported as early as week one. HS remains one of the most underserved diseases in dermatol…
  • will be available next year, with regulatory submissions to follow in the second half of 2…
  • 295. Other mechanisms such as anti-TL1A antibody are also being considered.

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 2

phase three program for RINVOC in HS is also nearing completion, where we remain on track for 16-week top-line results near the end of the year. Moving to atopic dermatitis, Zoom Locobart, phase two results were presented at the EADV Congress, demonstrating rapid and meaningful skin clearance and itch relief. Phase three studies are on track to begin later this

Passages & reports (2)
  • phase three program for RINVOC in HS is also nearing completion, where we remain on track …
  • demonstrating rapid and meaningful skin clearance and itch relief. Phase three studies are…

Speaker unclear

?year.

Passages & reports (1)
  • year.

Speaker 2

Turning to neuroscience, where in the third quarter, JUVMO was approved by the FDA for Parkinson's disease. Dopamine agonists have long been used to help manage symptoms and reduce reliance on oral levatopa escalation. However, currently available agents primarily target D2-D3 receptors, and their use has been limited by adverse events. As a selective D1-D5 receptor agonist, JuveMO demonstrated strong motor control and a favorable tolerability profile ?with low rates of dyskinesia, sedation, and impulse control disorder, which have historically impacted the use of dopamine agonists.

Additionally, long-term data continue to support a reduced reliance on oral levadopa when taking JUVMO. After more than a year and a half on JUVMO,
93% of patients had not increased their Levadopa dose, and 94% of patients with early Parkinson's disease had not started oral levitopa. Physicians and patients now have a treatment option that targets dopamine pathways differently and may reduce the difficult trade-offs associated with D2D3 agonists.

In psychiatry, the amraclidine dose escalation study has completed. The 150 milligram dose will be utilized
?in the monotherapy and adjunctive phase two studies in schizophrenia, with enrollment expected to begin by the end of this year. This new dose is five times the highest dose evaluated in the previous two pivotal trials. The 150 milligram dose was well tolerated and no new safety signals were identified.

We look forward to advancing this higher dose for schizophrenia, which may result in greater efficacy compared to prior studies. Doses have also been selected for the psychosis program, where phase two studies in Alzheimer's and Parkinson's disease are expected to begin
early next year. Moving to our psychedelic acid, Braticillosin, a phase three trial evaluating a single course acute treatment in major depressive disorder is expected to begin later this year.

We also remain on track for additional phase two data in monotherapy
MDD by year end, which will help inform the phase two study evaluating repeat dosing for chronic use. This MDD study, as well as phase two proof of concepts in post-traumatic stress, generalized anxiety, and obsessive compulsive disorders, are expected to begin in 2027. In migraine, positive top-line results were announced from the Phase III LUNA study, which evaluated CULYPTA for the preventive treatment of menstrual migraine.

No medicines are currently approved for menstrual
migraine attacks, which are considered more difficult to treat, more disabling, tend to last longer, and have a higher tendency to recur. This underscores the need for effective treatment strategies for this distinct disorder. ?In the Luna trial, CULYPTA demonstrated meaningful and statistically significant reductions in migraine days associated with the menstrual period, meeting the primary and all eight ranked secondary endpoints versus placebo.

A regulatory application will be submitted soon in Europe. Additionally,
phase three results for Ubrelvi in menstrual migraine prevention are expected near the end of the year, which will potentially support a submission in the US in early 2027. Moving to hematologic oncology. Positive top-line results were announced from the Phase III Cerveno trial evaluating attentamig monotherapy versus standard of care in heavily pretreated triple class exposed multiple myeloma patients.

AttentaMIG delivered statistically significant and clinically meaningful improvements in progression free survival and
overall response rates with a manageable safety profile, supporting its potential to become an important new treatment option for multiple myeloma. BCMA directed bi specifics and CAR T therapies have transformed multiple myeloma treatment. However, their adoption, particularly among community based centers, remains limited by adverse events such as CRS, neurotoxicity, and serious infections, as well as the need for specialized monitoring.

With a differentiated safety profile, simplified onboarding, and a more convenient
once-monthly dosing schedule after a single step-up dose, AtentamIG has the potential to streamline treatment and expand access across settings, including community-based clinics. A regulatory application was recently submitted to the FDA with an approval decision anticipated next year. Beyond the Chervino program, two new Phase III trials were recently initiated for a Tentamig, one in combination with pomolidomide in secondline plus multiple myeloma, and another as a monotherapy in patients with newly diagnosed light chain amyloidoses. ?

And
at the upcoming ASH meeting, early results from a phase two study evaluating atentameg plus derotumumab in frail, transplant ineligible frontline multiple myeloma will be presented, with a third phase three study potentially starting next year. Continuing with other HEMONT programs, positive top line results were announced from the Phase III EPCOR DLBCL II trial evaluating EPKI in combination with RCOP in frontline DLBCL.

The study demonstrated a statistically significant and clinically meaningful improvement in
progression-free survival compared to RCOP alone. EPKINLY plus RCOP showed an overwhelming treatment benefit at this interim analysis, reducing the risk of disease progression or death by 51% in a broad population covering patients with international prognostic index scores between two and five. Importantly, this is the first phase three study with a bi-specific antibody combination to demonstrate a progression-free survival benefit in frontline.

Supporting the potential for Fkinley plus RCOP to become a new standard of care in this
setting, Regulatory submissions are anticipated early next year. Turning to solid tumors, at the World Conference on Lung Cancer, results from a phase one study evaluating our PD1 VEGF bi-specific antibody, ABB 1480, in frontline non-small cell lung cancer were presented. These early data were particularly encouraging given the activity observed in PDL1 negative patients, a group which has traditionally been more difficult to treat.

A phase three study was recently initiated to evaluate 1480 in
combination with chemotherapy in frontline squamous and non-squamous small cell lung cancer. We also intend to move quickly to evaluate 1480 in combination with our ADCs across several tumor types. Two phase two studies evaluating 1480 plus TMABA were recently initiated, one one in non-small cell lung cancer and another in colorectal cancer. And a phase two combination study with ABB 706, our CES 6ADC, will begin next year in small cell lung cancer.

Passages & reports (30)
  • Turning to neuroscience, where in the third quarter, JUVMO was approved by the FDA for Par…
  • receptors, and their use has been limited by adverse events. As a selective D1-D5 receptor…
  • with
  • low rates of dyskinesia, sedation, and impulse control disorder, which have historically i…
  • 93% of patients had not increased their Levadopa dose, and 94% of patients with early Park…
  • trade-offs associated with D2D3 agonists. In psychiatry, the amraclidine dose escalation s…
  • in
  • the monotherapy and adjunctive phase two studies in schizophrenia, with enrollment expecte…
  • new safety signals were identified. We look forward to advancing this higher dose for schi…
  • early next year. Moving to our psychedelic acid, Braticillosin, a phase three trial evalua…
  • MDD by year end, which will help inform the phase two study evaluating repeat dosing for c…
  • expected to begin in 2027. In migraine, positive top-line results were announced from the …
  • migraine attacks, which are considered more difficult to treat, more disabling, tend to la…
  • In
  • the Luna trial, CULYPTA demonstrated meaningful and statistically significant reductions i…
  • phase three results for Ubrelvi in menstrual migraine prevention are expected near the end…
  • Phase III Cerveno trial evaluating attentamig monotherapy versus standard of care in heavi…
  • overall response rates with a manageable safety profile, supporting its potential to becom…
  • particularly among community based centers, remains limited by adverse events such as CRS,…
  • once-monthly dosing schedule after a single step-up dose, AtentamIG has the potential to s…
  • year. Beyond the Chervino program, two new Phase III trials were recently initiated for a …
  • And
  • at the upcoming ASH meeting, early results from a phase two study evaluating atentameg plu…
  • with other HEMONT programs, positive top line results were announced from the Phase III EP…
  • progression-free survival compared to RCOP alone. EPKINLY plus RCOP showed an overwhelming…
  • and five. Importantly, this is the first phase three study with a bi-specific antibody com…
  • setting, Regulatory submissions are anticipated early next year. Turning to solid tumors, …
  • in frontline non-small cell lung cancer were presented. These early data were particularly…
  • combination with chemotherapy in frontline squamous and non-squamous small cell lung cance…
  • initiated, one one in non-small cell lung cancer and another in colorectal cancer. And a p…

Moving to obesity, detailed results were presented at EASD from a phase one multiple ascending dose study evaluating ABB two nive in adults with a mean BMI of less than 30. We continue to be encouraged by the emerging profile for this long-acting AMLIN analog. In the study, 295 demonstrated meaningful weight loss across multiple dosing regimens, a manageable tolerability profile, and a PK profile that supports potentially differentiating dosing intervals of every other week or monthly.

A phase 1B
study in obese patients is ongoing with interim data anticipated around the end of this year. Additionally, a phase two trial in obese patients was recently initiated. Turning to aesthetics, we continue to work closely with the FDA to resolve outstanding matters related to the complete response letter for Bowie. Resubmission to the FDA is anticipated before the end of this year, with a regulatory decision expected in mid 2027.

Additionally, we are exploring a combination of Botox with BOE, which has the potential to deliver differentiated
efficacy by combining the rapid onset of BOE with the durable effects of Botox. A Phase II study recently began to evaluate this combination in globellar lines. In summary, we continue to make meaningful progress across all stages and therapeutic areas of our pipeline and look forward to several more important pipeline milestones during the remainder of this year and into 2027.

With that, I'll turn the call over to Scott. Thank you, RuPaul. Starting with our third quarter results, we reported

Passages & reports (6)
  • Moving to obesity, detailed results were presented at EASD from a phase one multiple ascen…
  • analog. In the study, 295 demonstrated meaningful weight loss across multiple dosing regim…
  • study in obese patients is ongoing with interim data anticipated around the end of this ye…
  • response letter for Bowie. Resubmission to the FDA is anticipated before the end of this y…
  • efficacy by combining the rapid onset of BOE with the durable effects of Botox. A Phase II…
  • pipeline and look forward to several more important pipeline milestones during the remaind…

Speaker 4

Unverified voice label

adjusted earnings

Passages & reports (1)
  • adjusted earnings

Speaker 2

per share

Passages & reports (1)
  • per share

Speaker unclear

?of $3.82, which is $0.07

Passages & reports (1)
  • of $3.82, which is $0.07

Speaker 4

above our guidance midpoint. These results include an 11 cent unfavorable impact from acquired IPRD expense. Total net revenues were $17.4 billion, reflecting robust operational growth of 10.5%, excluding a 0.2% unfavorable impact from foreign exchange. Adjusted gross margin was 85.1% of sales. Adjusted RD expense was 13.9% of sales, and adjusted SGA expense was 21.2% of sales. The adjusted operating margin was 48.7% of sales, which includes a 1.2% unfavorable impact from acquired IPRD expense.

Adjusted net interest expense was $688 million. The adjusted tax rate was 13.6%.

Passages & reports (3)
  • above our guidance midpoint. These results include an 11 cent unfavorable impact from acqu…
  • 0.2% unfavorable impact from foreign exchange. Adjusted gross margin was 85.1% of sales. A…
  • adjusted operating margin was 48.7% of sales, which includes a 1.2% unfavorable impact fro…

Turning to our financial outlook, we are raising our full year adjusted earnings per share guidance range by 11 cents at the midpoint to between $13.95 and $13.99. This guidance does not include acquired IPRD expense that may be incurred beyond the third quarter. We now expect total net revenues of approximately $67.8 billion, an increase of $200 million. At current rates, we continue to expect a roughly 0.5% favorable impact from foreign exchange on full-year sales growth.

Our revenue forecast now includes the following approximate assumptions for several of our key products and therapeutic areas. For immunology, we are increasing our global sales outlook to $34.9 billion. This assumes SkyRizi revenue of
$21.8 billion ?and Rinvoke revenue of $10.3 billion, reflecting increases for both brands based on continued strong momentum. In neuroscience, we now anticipate global revenues of $13 billion, an increase of $300 million, reflecting Vrailar sales of $4.2 billion, Botox therapeutic sales of $4.2 billion, and total oral CGRP sales of $3.1 billion.

For oncology, we are raising our global sales guidance to $6.6 billion. This now contemplates higher Venclexta sales of
$3.1 billion as well as lower Imbruvica sales of $2.1 billion. In aesthetics, our global sales outlook remains unchanged at $5 billion and now assumes higher Botox cosmetic sales of $2.8 billion, offset by lower expected revenues across products and other aesthetics. Moving to the PL for 2026, we continue to forecast full year adjusted gross margin above 84% of sales, adjusted RD expense of approximately $9.8 billion, and adjusted SGNA expense of approximately $14.5 billion.

We also anticipate an adjusted operating margin of approximately 46.7% of sales, which includes a roughly 1.8% unfavorable impact from acquired IPRD expense incurred through the
third quarter. Turning to the fourth quarter, we anticipate net revenues of approximately $18.4 billion, which includes a modestly unfavorable impact from foreign exchange. We also forecast adjusted earnings per share between $3.83 and $3.87. This guidance does not include acquired IPRD expense that may be incurred in the quarter.

Finally, AVI's strong business performance continues to support our capital allocation priorities. Our cash balance at the end of September was $10.8 billion,
and we generated approximately $14 billion of free cash flow in the first nine months of the year, which includes nearly $2.7 billion of SkyRIZI royalty payments. This robust free cash flow supports a strong and growing quarterly dividend, which we are increasing by 0.2% to $1.82 per share, beginning with a dividend payable in February of 2027, as well as capacity for additional business development, where we continue to assess external innovation across all of our key growth areas.

Following the recent close of the Apogee transaction, we
remain on track to achieve a net leverage ratio of two times over the next two to three years.

Passages & reports (15)
  • Turning to our financial outlook, we are raising our full year adjusted earnings per share…
  • beyond the third quarter. We now expect total net revenues of approximately $67.8 billion,…
  • growth. Our revenue forecast now includes the following approximate assumptions for severa…
  • $21.8 billion
  • and
  • Rinvoke revenue of $10.3 billion, reflecting increases for both brands based on continued …
  • billion, Botox therapeutic sales of $4.2 billion, and total oral CGRP sales of $3.1 billio…
  • $3.1 billion as well as lower Imbruvica sales of $2.1 billion. In aesthetics, our global s…
  • products and other aesthetics. Moving to the PL for 2026, we continue to forecast full yea…
  • approximately $14.5 billion. We also anticipate an adjusted operating margin of approximat…
  • third quarter. Turning to the fourth quarter, we anticipate net revenues of approximately …
  • and $3.87. This guidance does not include acquired IPRD expense that may be incurred in th…
  • and we generated approximately $14 billion of free cash flow in the first nine months of t…
  • to $1.82 per share, beginning with a dividend payable in February of 2027, as well as capa…
  • remain on track to achieve a net leverage ratio of two times over the next two to three ye…

Speaker unclear

?In

Passages & reports (1)
  • In

Speaker 4

closing, AVI has once again delivered outstanding top and bottom line results, and our financial outlook remains very strong. With that, I'll turn the call back over to Liz.

Passages & reports (1)
  • closing, AVI has once again delivered outstanding top and bottom line results, and our fin…

Speaker unclear

?Thanks, Scott. We will now open

Passages & reports (1)
  • Thanks, Scott. We will now open

Questions & answers

Speaker 1

the call for questions. In the interest of hearing from as many analysts as possible over the remainder of the call, we ask that you please limit your questions to one or two. Operator, we'll take the first question, please.

Passages & reports (1)
  • the call for questions. In the interest of hearing from as many analysts as possible over …

Speaker 0

Thank you. If you would like to ask a question, please signal it by pressing star one on your telephone keypad. If you're using a speakerphone, please make sure your meet function is turned off to allow your signal to reach our equipment. Again, please press star one to ask a question. We'll go first to Vamil Devon with Google Guggenheim Securities.

Passages & reports (2)
  • Thank you. If you would like to ask a question, please signal it by pressing star one on y…
  • to Vamil Devon with Google Guggenheim Securities.

Speaker unclear

?Great. Thanks. Uh thanks for taking my questions

Passages & reports (1)
  • Great. Thanks. Uh thanks for taking my questions

Speaker 2

and uh thanks for all the information on the

Passages & reports (1)
  • and uh thanks for all the information on the

Speaker unclear

?call.

Passages & reports (1)
  • call.

Speaker 5

Unverified voice label

Maybe ?if I could um ?just as I know

Passages & reports (5)
  • Maybe
  • if I could
  • um
  • just
  • as I know

Speaker unclear

?you're not getting formal guidance from

Passages & reports (1)
  • you're not getting formal guidance from

Speaker 5

next year yet, ?but if I could just ask about as we think about updating our models today, any sort of key pushes or polls as we think about next year in terms of um dynamics to keep in mind. And also just at this point, anything you can share around payer discussions

Passages & reports (3)
  • next year yet,
  • but
  • if I could just ask about as we think about updating our models today, any sort of key pus…

Speaker unclear

?or

Passages & reports (1)
  • or

Speaker 5

written book and how we should think about

Passages & reports (1)
  • written book and how we should think about

Speaker unclear

?this is

Passages & reports (1)
  • this is

Speaker 2

Rob. I'll take the first question and Jeff will take the second question. So as we typically do, ?uh we'll provide twenty twenty seven guidance on the Q four call, but we are certainly exiting this year in a very strong position. Our sales earnings growth in 2026 will be the second highest relative to our peers. And you know, we expect to deliver top-tier growth again next year.

When I look at Sky
Rizzy and RinVoke, they're delivering incredible growth of six billion combined this year, despite already being on the market for eight years and with more competition. If you think about where that growth is coming from, that's six billion, three of it is an IBD across Rinvoque and Sky Rizzy, with obviously competitive entry in that space. Two billion of that growth is in SkyRIZI Soriatic with the competitive entry in that space as well.

So we're seeing, despite increased competition, just tremendous growth from SkyRizia and RinVoke. And we have several catalysts that will help drive their growth next year and beyond, including sub Q induction for SkyRizia and
Crohn's with higher efficacy and more convenient dosing that will give us an even stronger competitive physician. We'll see SkyRizzy head-to-head data versus Antivio, which will bolster our position in UC.

And we will launch two new DERM indications for Rinvoke, both Vitiligo and alopecia ariata. So we have very strong momentum in
immunology to continue delivering robust growth next year and beyond. Then in neuroscience, you know, we're on track to deliver growth of 20% this year, which has made us the industry leader. I expect the strong demand to continue for Valar, Ubrel V, Culypta, and Violet, in addition to Botox Therapeutic.

Juvmo, as was mentioned
on the call today, it's our new Parkinson's therapy. That will also contribute to the growth, although the ramp will be more significant in 28 and beyond given timing of Medicare coverage. And then I would also keep in mind that the IRA price for Railar will begin in 2027. So you should be modeling that in as well, although I'd say m many of the cell side models have appeared to have modeled that in.

But clearly, I mean we have a lot of momentum across our business to drive strong top tier growth again next year.

Passages & reports (9)
  • Rob. I'll take the first question and Jeff will take the second question. So as we typical…
  • uh
  • we'll provide twenty twenty seven guidance on the Q four call, but we are certainly exitin…
  • Rizzy and RinVoke, they're delivering incredible growth of six billion combined this year,…
  • that space. Two billion of that growth is in SkyRIZI Soriatic with the competitive entry i…
  • Crohn's with higher efficacy and more convenient dosing that will give us an even stronger…
  • immunology to continue delivering robust growth next year and beyond. Then in neuroscience…
  • on the call today, it's our new Parkinson's therapy. That will also contribute to the grow…
  • that in as well, although I'd say m many of the cell side models have appeared to have mod…

Speaker 3

Yeah, hi Bommel, it's Jeff. So you know we are uh uh beginning to close all of the arrangements with the uh with the large PBMs and payers. And I would say overall it's it's a very consistent story as prior years. Uh you know, our portfolio of products will have uh very strong access and it's based on a lot of the demand and the profiles that we have.

The physicians really like these products, they're leading products across uh almost all of our categories, and so we anticipate uh
?you know very good payer access. In terms of the immunology uh approach, you know, that low single-digit sort of rebate concession is something that I would continue to think about in your modeling. You know, channels move around a bit, but that's typically been our pattern, and we we continue to think that that's a good uh a good level of guidance there in terms of as we move into 27 in terms of payer access.

And I I couldn't fully hear your question, but uh in terms of Rinvoke, very consistent answer, and we anticipate,
?you know, with the pending approvals of uh VitaliGo and Alapecia Ariada as we move into 27 that those that those new indications will also be reflected with favorable access as we as we move into the uh new year.

Passages & reports (7)
  • Yeah, hi Bommel, it's Jeff. So you know we are uh uh beginning to close all of the arrange…
  • and it's based on a lot of the demand and the profiles that we have. The physicians really…
  • you
  • know very good payer access. In terms of the immunology uh approach, you know, that low si…
  • good uh a good level of guidance there in terms of as we move into 27 in terms of payer ac…
  • you
  • know, with the pending approvals of uh VitaliGo and Alapecia Ariada as we move into 27 tha…

Speaker unclear

?Thanks,

Passages & reports (1)
  • Thanks,

Speaker 1

Family. Operator, next question, please.

Passages & reports (1)
  • Family. Operator, next question, please.

Speaker 0

We'll go next to Chris Schott with JP Morgan.

Passages & reports (1)
  • We'll go next to Chris Schott with JP Morgan.

Speaker unclear

?Thanks so much. I I just wanted to

Passages & reports (1)
  • Thanks so much. I I just wanted to

Speaker 2

follow up on the

Passages & reports (1)
  • follow up on the

Speaker unclear

?full data from the Sky Rizzy Sub Q induction in Crohn's and that recent approval. Can you just help frame out the opportunity here? I guess

Passages & reports (1)
  • full data from the Sky Rizzy Sub Q induction in Crohn's and that recent approval. Can you …

Speaker 6

Unverified voice label

specifically how are you ?thinking about market share dynamics going forward and and I guess how quickly do you think that could could play through as you as you think about just kind of the ramp of SkyRizi from ?here? And and then my second question was was was on the pipeline and the role of SkyRizi in the Alpha 4 beta seven and I B D just following the the phase two data, are you thinking of this as a drug that's uh for for later lines of therapy or something that could be earlier in the in the treatment paradigm?

Just maybe kind of talk a bit more about how you're seeing that fit relative to SkyRizy and just other products being developed in the space. Thank

Passages & reports (6)
  • specifically how are you
  • thinking
  • about market share dynamics going forward and and I guess how quickly do you think that co…
  • here? And
  • and then my second question was was was on the pipeline and the role of SkyRizi in the Alp…
  • in the in the treatment paradigm? Just maybe kind of talk a bit more about how you're seei…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 3

Yeah, hi Chris. It's Jeff. I'll take the commercial stuff, and maybe RuPaul can give a quick flavor over the new data that was announced at uh ACG and UEGW. Yeah,

Passages & reports (1)
  • Yeah, hi Chris. It's Jeff. I'll take the commercial stuff, and maybe RuPaul can give a qui…

Speaker 2

so on the on

Passages & reports (1)
  • so on the on

Speaker unclear

?the SubQ data set, what what you what you heard from us with uh was

Passages & reports (1)
  • the SubQ data set, what what you what you heard from us with uh was

Speaker 3

was very strong data, and when we compare it with our own SkyRizi

Passages & reports (1)
  • was very strong data, and when we compare it with our own SkyRizi

Speaker 2

IV

Passages & reports (1)
  • IV

Speaker 3

induction, the it's numerically higher and quite substantially higher in that treatment

Passages & reports (1)
  • induction, the it's numerically higher and quite substantially higher in that treatment

Speaker 2

naive

Passages & reports (1)
  • naive

Speaker 3

setting,

Passages & reports (1)
  • setting,

Speaker 2

which

Passages & reports (1)
  • which

Speaker unclear

?is the current uh positioning of

Passages & reports (1)
  • is the current uh positioning of

Speaker 2

SkyRISI currently in uh Crohn's NUC. So it'll further

Passages & reports (1)
  • SkyRISI currently in uh Crohn's NUC. So it'll further

Speaker 3

support that exact positioning.

Passages & reports (1)
  • support that exact positioning.

Speaker 2

Because

Passages & reports (1)
  • Because

Speaker 3

recall ?uh with RinVoke having uh a little bit of a label inspect uh expansion

Passages & reports (3)
  • recall
  • uh
  • with RinVoke having uh a little bit of a label inspect uh expansion

Speaker 2

that has allowed us uh for those patients that are deemed inappropriate for an anti TNF who can then use

Passages & reports (1)
  • that has allowed us uh for those patients that are deemed inappropriate for an anti TNF wh…

Speaker 3

Rinvoke potentially right after Skyrisi. So

Passages & reports (1)
  • Rinvoke potentially right after Skyrisi. So

Speaker 2

that petition that positioning, I should say, has been further substantially strengthened with this subcutaneous offering. ?So that's one point. And maybe I'll I'll touch on the Alpha 4 Beta 7 combo and then go back ?to Jeff.

Passages & reports (5)
  • that petition that positioning, I should say, has been further substantially strengthened …
  • So
  • that's one point. And maybe I'll I'll touch on the Alpha 4 Beta 7 combo and then go back
  • to
  • Jeff.

Speaker 3

So, Chris,

Passages & reports (1)
  • So, Chris,

Speaker 2

I

Passages & reports (1)
  • I

Speaker 3

it what we saw here was very strong efficacy in later lines, including patients who already used P19s, already used JAC inhibitors like RinVoke. However, we

Passages & reports (1)
  • it what we saw here was very strong efficacy in later lines, including patients who alread…

Speaker 2

also saw strong data in earlier lines.

Passages & reports (1)
  • also saw strong data in earlier lines.

Speaker 3

And we anticipate

Passages & reports (1)
  • And we anticipate

Speaker 2

being able to see that

Passages & reports (1)
  • being able to see that

Speaker unclear

?in Crohn's, and in particular, a lot

Passages & reports (1)
  • in Crohn's, and in particular, a lot

Speaker 2

of excitement from our thought leaders in how this combination can look in earlier lines of ulcerative colitis. Can we get much stronger disease control early in patients rather than waiting for a step-up

Passages & reports (1)
  • of excitement from our thought leaders in how this combination can look in earlier lines o…

Speaker 3

in care? This can

Passages & reports (1)
  • in care? This can

Speaker 2

potentially modify the disease as I was describing based on gene expression. Could you have much better outcomes in the longer term reductions in hospital visits and surgeries? So as we move this forward, we'd be looking at early patients and in later lines of patients. And that's in Crohn's and UC. We would explore that with 3A2, which is alpha-4 beta 7, as well as with our TL1A antibody as

Passages & reports (2)
  • potentially modify the disease as I was describing based on gene expression. Could you hav…
  • We would explore that with 3A2, which is alpha-4 beta 7, as well as with our TL1A antibody…

Speaker unclear

?well. Yeah,

Passages & reports (1)
  • well. Yeah,

Speaker 3

and Chris, in terms of your commercial question, so uh we are excited about the recent sub Q approval and our field teams already are out there promoting this affirm data ?uh that's now reflected in the US label. So I think what's important, as RuPaul said, these endoscopic endpoints are really resonating uh for several years now with the gastroenterologist, and that's that's the single largest market value driver of what preference is.

And so when our our experts and our I B D experts, our
gastros, look at this uh affirm data, it's quite it's quite striking. So it's sort of very, very high rates, higher than our IV. And when they look, of course, it's cross-study comparisons, when they look across not just IL-23 induction, but every single induction study that's been done to date, it really stands out.

So as we've talked about over the last few quarters, you know, the in-play share is roughly 50 50 in IBD versus the main competitor. We would anticipate uh certainly an acceleration in Crohn's uh where we have that approval. Now in terms of timing as to when we've seen we'd see that
uh it will take us probably you know 60 days maybe a little bit longer to get full access.

That's just the normal cycle of the approval of something like this with our contracts. Uh so in the uh certainly the first part of the year into the second quarter uh we anticipate a a
pretty rapid uh share acceleration there.

Passages & reports (7)
  • and Chris, in terms of your commercial question, so uh we are excited about the recent sub…
  • uh
  • that's now reflected in the US label. So I think what's important, as RuPaul said, these e…
  • gastros, look at this uh affirm data, it's quite it's quite striking. So it's sort of very…
  • stands out. So as we've talked about over the last few quarters, you know, the in-play sha…
  • uh it will take us probably you know 60 days maybe a little bit longer to get full access.…
  • pretty rapid uh share acceleration there.

Speaker unclear

?And Chris

Passages & reports (1)
  • And Chris

Speaker 2

let me add uh we we're also very pleased with the updated tuberculosis language that gives ?uh physicians more flexibility. So that was important based on years

Passages & reports (3)
  • let me add uh we we're also very pleased with the updated tuberculosis language that gives
  • uh
  • physicians more flexibility. So that was important based on years

Speaker unclear

?of data.

Passages & reports (1)
  • of data.

Speaker 7

Unverified voice label

Uh so we're we're excited about that. And then recall having the sub Q option up front and then having every eight

Passages & reports (1)
  • Uh so we're we're excited about that. And then recall having the sub Q option up front and…

Speaker 3

week dosing,

Passages & reports (1)
  • week dosing,

Speaker 2

that's ?another area we can continue to emphasize that makes

Passages & reports (3)
  • that's
  • another
  • area we can continue to emphasize that makes

Speaker unclear

?SkyRISI so unique.

Passages & reports (1)
  • SkyRISI so unique.

Speaker 1

Thanks, Chris. Operator, next question, please.

Passages & reports (1)
  • Thanks, Chris. Operator, next question, please.

Speaker 0

We have Louise Chin from Scotia Bank.

Passages & reports (1)
  • We have Louise Chin from Scotia Bank.

Speaker unclear

?Hi, thanks for taking my questions. I wanted to ask you for

Passages & reports (1)
  • Hi, thanks for taking my questions. I wanted to ask you for

Speaker 7

emraquidine, what gives you confidence that the underdosing was really the issue in the prior studies and what you're thinking, related thinking on the market opportunity. And then the other thing I want to ask you is that you have a lot of potentially best in class assets in your pipeline. Maybe if you could highlight to us which one or which ones you're most excited about that you think are underappreciated by the street, that would be very helpful.

Thank

Passages & reports (2)
  • emraquidine, what gives you confidence that the underdosing was really the issue in the pr…
  • highlight to us which one or which ones you're most excited about that you think are under…

Speaker unclear

?you. Hey Louise,

Passages & reports (1)
  • you. Hey Louise,

Speaker 2

this is RuPaul. I'll take that.

Passages & reports (1)
  • this is RuPaul. I'll take that.

Speaker 3

With amraclidine,

Passages & reports (1)
  • With amraclidine,

Speaker 2

we did observe lower receptor occupancy and variability in PK. And again, that's uh ?uh one-fifth of the dose that we're going to take forward at 150 milligram. So the the confidence is more around the PK and receptor occupancy and less heterogeneity at the higher dose. So that will drive

Passages & reports (3)
  • we did observe lower receptor occupancy and variability in PK. And again, that's uh
  • uh
  • one-fifth of the dose that we're going to take forward at 150 milligram. So the the confid…

Speaker 3

uh hopefully more predictability there, and we

Passages & reports (1)
  • uh hopefully more predictability there, and we

Speaker 2

continue to like the the benefits of once a day dosing and the fact that we don't need another complementary drug to offset adverse events. And thus far we've seen

Passages & reports (1)
  • continue to like the the benefits of once a day dosing and the fact that we don't need ano…

Speaker 3

low GI adverse events. So we think that uh will be a nice benefit in monotherapy and adjunctive. We are going into phase two so we'll be able to test this out. So that's I would say drug specific. And then also

Passages & reports (1)
  • low GI adverse events. So we think that uh will be a nice benefit in monotherapy and adjun…

Speaker 2

study specific. We were able to do deep dives into the empower studies and our own Vrailar studies. And from that, we can learn better approaches to reducing placebo responses. So there's a variety of factors that we're going to implement in all of our trials going forward. And

Passages & reports (2)
  • study specific. We were able to do deep dives into the empower studies and our own Vrailar…
  • trials going forward. And

Speaker 3

hopefully that will also support favorable

Passages & reports (1)
  • hopefully that will also support favorable

Speaker 2

outcomes in the

Passages & reports (1)
  • outcomes in the

Speaker 3

future. And if we see that, we would pivot very rapidly to phase three.

Passages & reports (1)
  • future. And if we see that, we would pivot very rapidly to phase three.

Speaker 2

Some things that we're excited about, staying in psychiatry. You heard us talk about breticillosin, MDD is important, but also PTSD, anxiety, and OCD are where we're going to look at phase two. So that's potentially underappreciated. But I do have to, I would say, mention again entamig. And that one is in our pipeline. We have multiple additional phase threes that are prepared and ready to ?go.

And this asset is quite near term, has a potential to launch uh around the middle of next year. And that is a very exciting asset as as we've described. The CRS rates are very low, and grade m almost all grade one and and very few
grade two, and just a single case of ICANNs after a single step up dose. And then you can immediately go to monthly dosing.

So this is very well differentiated across anything available currently in the TCE space. So we're very excited about that one, and we believe
that the street uh continues to underappreciate that asset and our opportunity in myeloma with uh Intentimig and then even potentially with our uh anti C D thirty eight uh BCMA T cell engager tri-specific, which we are trying to move very quickly into phase three.

That's also a very unique opportunity.
?And maybe Jeff wants to comment.

Passages & reports (9)
  • Some things that we're excited about, staying in psychiatry. You heard us talk about breti…
  • mention again entamig. And that one is in our pipeline. We have multiple additional phase …
  • go.
  • And this asset is quite near term, has a potential to launch uh around the middle of next …
  • grade two, and just a single case of ICANNs after a single step up dose. And then you can …
  • that the street uh continues to underappreciate that asset and our opportunity in myeloma …
  • phase three. That's also a very unique opportunity.
  • And
  • maybe Jeff wants to comment.

Speaker 3

So I I would I would agree. Uh we we we've been we've been surprised, maybe less so more recently, but Intentamig is a is a fantastic profile. Uh and not only uh will it allow us to enter myeloma, I think, very, very rapidly here, uh we have uh we have multiple drugs behind it. And so this is a clear strategy that is uh that's underappreciated.

I think more recently, because RuPaul had such a phenomenal discussion over some of these readouts, uh, very excited about Epkinley and Frontline uh uh NHL. This is really the big market value driver uh uh in terms of uh
that particular product, and the the readout was spectacular. I would have to say as well, um, which is maybe not as big a surprise, but the ability to continue to raise the standard of care in IBD uh with 466, this combination platform, and we've got multiple shots on goal there with uh combination TL1A that is very, very close.

So the ability to bring multiple assets uh to basically uh navigate really the exceptional performance of SkyRizi as we move into the 2030s uh is also a a profound opportunity for the company.

Passages & reports (4)
  • So I I would I would agree. Uh we we we've been we've been surprised, maybe less so more r…
  • it. And so this is a clear strategy that is uh that's underappreciated. I think more recen…
  • that particular product, and the the readout was spectacular. I would have to say as well,…
  • TL1A that is very, very close. So the ability to bring multiple assets uh to basically uh …

Speaker unclear

?And

Passages & reports (1)
  • And

Speaker 2

Louise, this is Rob, just to add on here, we've mentioned he tend to Mig is you know it's a multi-billion dollar opportunity ?that uh is significantly undercalled in many street models. I would add TMAB A to that as well, similar, you know, multi-billion dollar opportunity, significantly undercalled many street models. And then with if you look at the neuroscience business, we've said we we believe we have three five billion dollar plus franchises covering psychiatry, migraine, and Parkinson's, and we're still not seeing that reflected in the you know in longer term consensus. ?

Uh
I would also add Zumi Loki bar uh as as upside to you know to the street versus you know what we're expecting. So uh as I look at the the portfolio we have you know the as we look at longer term growth, you know, twenty th in the twenty thirties, uh, we have a number of upside opportunities that are not yet reflected in street models.

Passages & reports (7)
  • Louise, this is Rob, just to add on here, we've mentioned he tend to Mig is you know it's …
  • that
  • uh is significantly undercalled in many street models. I would add TMAB A to that as well,…
  • Parkinson's, and we're still not seeing that reflected in the you know in longer term cons…
  • Uh
  • I would also add Zumi Loki bar uh as as upside to you know to the street versus you know w…
  • a number of upside opportunities that are not yet reflected in street models.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 1

you, Louise. Operator, next question, please.

Passages & reports (1)
  • you, Louise. Operator, next question, please.

Speaker 0

Welcome next to Chung Wen with RBC.

Passages & reports (1)
  • Welcome next to Chung Wen with RBC.

Speaker 5

Hi guys. Um, my first question is just on 340B. It's been a persistent challenge for the industry. Um so it was interesting to see that earlier the month in this month that you're taking part in this three forty B

Passages & reports (1)
  • Hi guys. Um, my first question is just on 340B. It's been a persistent challenge for the i…

Speaker 3

pilot launch uh for next year. So that's for

Passages & reports (1)
  • pilot launch uh for next year. So that's for

Speaker 5

Imbruvica, Linzes, and Vraila. Can you just walk us through the strategic rationale for participating there? Are there any potential growth to net improvements from the reduced duplicate discounts, or do you think we could still expect a headwind

Passages & reports (1)
  • Imbruvica, Linzes, and Vraila. Can you just walk us through the strategic rationale for pa…

Speaker unclear

?from the

Passages & reports (1)
  • from the

Speaker 3

broader 340B exposure? Just really wondering how material the benefits could be

Passages & reports (1)
  • broader 340B exposure? Just really wondering how material the benefits could be

Speaker 5

here.

Passages & reports (1)
  • here.

Speaker 3

And then on

Passages & reports (1)
  • And then on

Speaker 5

aesthetics, could you just give us an update on Trinibot E following the CRL and your just timelines for resubmission. Just how should we think about that? Cheers.

Passages & reports (1)
  • aesthetics, could you just give us an update on Trinibot E following the CRL and your just…

Speaker 2

Simon, this is Rob. I'll take your first question on 340B. Yes, I mean we are very focused on curbing the abuse in the program. And we are very supportive of the original intent of the program, which was to help SafetyNet hospitals serve the most vulnerable populations. But unfortunately, ?you know, today we have an outdated and overly broad definition of a 340B patient, which has led to significant program abuse. ?

And
that ultimately drives higher health care costs for employers, taxpayers, and patients, and it takes RD investment away from the industry. But that said, we are encouraged by the bipartisan support we are seeing across both the House and Senate on a few proposals that can bring greater transparency and accountability. And that's really what it's about. It's about driving more transparency and accountability, which is also what I believe this rebate pilot will accomplish.

It's another opportunity to provide that transparency to ensure that this program ultimately serves its original intent to benefit patients and not steal investment away from R D. I think it's too early to call
uh a a financial impact. We'll have to see how this plays out. We certainly uh you know manage the duplicate discounts well. Um we have good visibility to that.

So I'd say, you know, we've been managing through it. There has been, though, uh profound growth in this program that I think the entire
industry has been seeing, which is why we're advocating uh for policies that curb the abuse that we're seeing. ?And it's RuPaul on the TrinityBot question. Recall that the CRL was not due to uh any particular issues around safety or

Passages & reports (10)
  • Simon, this is Rob. I'll take your first question on 340B. Yes, I mean we are very focused…
  • you
  • know, today we have an outdated and overly broad definition of a 340B patient, which has l…
  • And
  • that ultimately drives higher health care costs for employers, taxpayers, and patients, an…
  • it's about. It's about driving more transparency and accountability, which is also what I …
  • uh a a financial impact. We'll have to see how this plays out. We certainly uh you know ma…
  • industry has been seeing, which is why we're advocating uh for policies that curb the abus…
  • And
  • it's RuPaul on the TrinityBot question. Recall that the CRL was not due to uh any particul…

Speaker 3

efficacy.

Passages & reports (1)
  • efficacy.

Speaker 2

It was on CMC

Passages & reports (1)
  • It was on CMC

Speaker unclear

?assessments, and we're gathering that data for the agency, and we will resubmit

Passages & reports (1)
  • assessments, and we're gathering that data for the agency, and we will resubmit

Speaker 3

at the end of this year, and we anticipate a six-month review. So we think the middle

Passages & reports (1)
  • at the end of this year, and we anticipate a six-month review. So we think the middle

Speaker unclear

?of next year

Passages & reports (1)
  • of next year

Speaker 2

in the US. And while this is ongoing, we are also submitting

Passages & reports (1)
  • in the US. And while this is ongoing, we are also submitting

Speaker unclear

?in other countries across the

Passages & reports (1)
  • in other countries across the

Speaker 2

globe. We already ?have European approval

Passages & reports (3)
  • globe. We already
  • have
  • European approval

Speaker unclear

?and as well as Canada. Thank

Passages & reports (1)
  • and as well as Canada. Thank

Speaker 1

you, Trong. Operator, next question, please.

Passages & reports (1)
  • you, Trong. Operator, next question, please.

Speaker 0

Yes, we will go next to Jason Gerberry with Bank of America.

Passages & reports (1)
  • Yes, we will go next to Jason Gerberry with Bank of America.

Speaker unclear

?Hey guys, uh thanks for taking my question. Mine was just

Passages & reports (1)
  • Hey guys, uh thanks for taking my question. Mine was just

Speaker 2

on ABB 466, and if you could talk about are there any triggers to potentially move this into phase three faster? I know you have the interim data for the phase two B with the

Passages & reports (1)
  • on ABB 466, and if you could talk about are there any triggers to potentially move this in…

Speaker 7

higher dose integrant. I imagine that's something that you're curious to see the results from before going to phase three, but wondering to the extent that you might be rate limited just by the co-formulation work and that's put the hard and fast kind ?of uh 2028 start uh on the phase three program. Thanks.

Passages & reports (3)
  • higher dose integrant. I imagine that's something that you're curious to see the results f…
  • of
  • uh 2028 start uh on the phase three program. Thanks.

Speaker unclear

?Uh

Passages & reports (1)
  • Uh

Speaker 2

hey Jason, it's RuPaul. So we do have built-in uh interims in in this next uh data ?set that that's going forward. Uh a few things that we're gonna do

Passages & reports (3)
  • hey Jason, it's RuPaul. So we do have built-in uh interims in in this next uh data
  • set
  • that that's going forward. Uh a few things that we're gonna do

Speaker unclear

?to assess uh

Passages & reports (1)
  • to assess uh

Speaker 3

382

Passages & reports (1)
  • 382

Speaker unclear

?exposure

Passages & reports (1)
  • exposure

Speaker 2

response. ?One thing to help speed things up is look at the data and run assays more often than you typically would and not waiting for the

Passages & reports (3)
  • response.
  • One thing to
  • help speed things up is look at the data and run assays more often than you typically woul…

Speaker unclear

?end.

Passages & reports (1)
  • end.

Speaker 3

The other thing we will also see is for the phase two study that we were just talking about here today, we will we've shown about 80% of the data. We'll get 100% of that data by the end of this year, early next year. ?And that'll ?let us rerun some of these models and to see if if we continue to observe that exposure response, lack of plateau for 382.

Sometimes with greater

Passages & reports (5)
  • The other thing we will also see is for the phase two study that we were just talking abou…
  • And
  • that'll
  • let us
  • rerun some of these models and to see if if we continue to observe that exposure response,…

Speaker 2

sample size, you could see things move in either direction. And while that's occurring, we'll start generating more data on the combo.

Passages & reports (1)
  • sample size, you could see things move in either direction. And while that's occurring, we…

Speaker unclear

?So if something is looking good, then we can speed up

Passages & reports (1)
  • So if something is looking good, then we can speed up

Speaker 3

the trial ?in a way by dropping the arm that's you know the current standard dose.

Passages & reports (3)
  • the trial
  • in
  • a way by dropping the arm that's you know the current standard dose.

Speaker 2

Alternatively, if we are seeing that the efficacy

Passages & reports (1)
  • Alternatively, if we are seeing that the efficacy

Speaker 3

is shouldering ?at a particular dose, then we don't have to continue the high dose, and then we can pivot uh

Passages & reports (3)
  • is shouldering
  • at a
  • particular dose, then we don't have to continue the high dose, and then we can pivot uh

Speaker 2

to the standard ?dose that we've already studied, gather some more data

Passages & reports (3)
  • to the standard
  • dose that we've already
  • studied, gather some more data

Speaker unclear

?there, be ready for regulators, and then potentially move into phase

Passages & reports (1)
  • there, be ready for regulators, and then potentially move into phase

Speaker 2

three sooner. It's hard to commit now. I would say there is some potential that we could start phase threes

Passages & reports (1)
  • three sooner. It's hard to commit now. I would say there is some potential that we could s…

Speaker unclear

?at the end of 2027.

Passages & reports (1)
  • at the end of 2027.

Speaker 2

We'll come back to see if that's possible, but I I haven't ruled that

Passages & reports (1)
  • We'll come back to see if that's possible, but I I haven't ruled that

Speaker 3

out based ?on our ability to look at the data on an interim basis.

Passages & reports (3)
  • out based
  • on
  • our ability to look at the data on an interim basis.

Speaker 1

Thanks,

Passages & reports (1)
  • Thanks,

Speaker 2

Jason.

Passages & reports (1)
  • Jason.

Speaker 1

Operator, next question,

Passages & reports (1)
  • Operator, next question,

Speaker unclear

?please.

Passages & reports (1)
  • please.

Speaker 0

We'll go next to Simon Baker with Rothschild Comp and Company Redburn.

Passages & reports (1)
  • We'll go next to Simon Baker with Rothschild Comp and Company Redburn.

Speaker unclear

?Thanks for taking my question. This is

Passages & reports (1)
  • Thanks for taking my question. This is

Speaker 7

a key though for

Passages & reports (1)
  • a key though for

Speaker unclear

?Simon Baker. I have a quick question on Ep Kingley in first line large B-soline firmware. So given your

Passages & reports (1)
  • Simon Baker. I have a quick question on Ep Kingley in first line large B-soline firmware. …

Speaker 7

competitors developing a different

Passages & reports (1)
  • competitors developing a different

Speaker unclear

?combination regimen, any thoughts about

Passages & reports (1)
  • combination regimen, any thoughts about

Speaker 7

the competitiveness of you of Epkinney based regimen? Maybe just a quick follow-up on Epkini as well. So, how should we think about the launch trajectory of uh Epkinley in first line large based on the informal? Thank

Passages & reports (1)
  • the competitiveness of you of Epkinney based regimen? Maybe just a quick follow-up on Epki…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Maybe I'll start and then and then Jeff will comment. What we like about the approach with uh Epkinle with RCOP is that RCHOP is very familiar, it's very well known across the globe, and there's a simplicity of just adding Epkinley uh to a very well known treatment regimen.

Passages & reports (2)
  • Maybe I'll start and then and then Jeff will comment. What we like about the approach with…
  • regimen.

Speaker unclear

?So we think there's already a benefit there. And then you also don't have to add uh

Passages & reports (1)
  • So we think there's already a benefit there. And then you also don't have to add uh

Speaker 3

two novel

Passages & reports (1)
  • two novel

Speaker 2

agents to a regiment. This would just be a single novel uh to RCHOP that people understand very well. So from an RD standpoint, uh we're we're excited about that, and that's what we hear from clinicians that for them it'll be relatively uh simple approach.

Passages & reports (1)
  • agents to a regiment. This would just be a single novel uh to RCHOP that people understand…

Speaker 3

Yeah, and I think that uh as I mentioned, I mean that that that frontline uh potential is clearly the largest commercial opportunity. We had always known that that was a larger commercial opportunity with our partner GenMab, but to see the strength of the data, it's it's quite striking. So uh we do believe despite you know what we may see from the competitor readout that this is a very very simple approach.

It's going to play extremely well around the world because there's a there's a very uh variability over uh countries on how they view poly V, uh the reimbursement of Polly V. And then again, you
have a novel, two novel novels, uh, it starts to build up the cost. So the exquisite simplicity of what we've done in front line with Apkinley has resonated uh very much with the thought leaders around the world.

And I think it will resonate very, very rapidly with the HTAs and other payers. And
so we anticipate uh, you know, as we move towards approvals, and as Ruppel mentioned, we'll be uh moving quickly with the regulatory filings here. uh I would expect uh quite a rapid adoption of that transformational uh indication.

Passages & reports (4)
  • Yeah, and I think that uh as I mentioned, I mean that that that frontline uh potential is …
  • despite you know what we may see from the competitor readout that this is a very very simp…
  • have a novel, two novel novels, uh, it starts to build up the cost. So the exquisite simpl…
  • so we anticipate uh, you know, as we move towards approvals, and as Ruppel mentioned, we'l…

Speaker 4

And this is Scott, I would just just re make sure everyone recalls that with respect to that product um the partnership ?that we have with GMAB, there's partnership economics. So we are not booking sales, the full sales in the US, ?uh Puerto Rico, and Japan. We're booking a profit share, so it's a ?a little bit of a different impact on the revenue line.

Passages & reports (7)
  • And this is Scott, I would just just re make sure everyone recalls that with respect to th…
  • that we
  • have with GMAB, there's partnership economics. So we are not booking sales, the full sales…
  • uh
  • Puerto Rico, and Japan. We're booking a profit share, so it's a
  • a
  • little bit of a different impact on the revenue line.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 1

you for the question. Operator, next question, please.

Passages & reports (1)
  • you for the question. Operator, next question, please.

Speaker 0

We'll go next to Terrence Flynn with Morgan Stanley.

Passages & reports (1)
  • We'll go next to Terrence Flynn with Morgan Stanley.

Speaker 2

Great. Thanks for taking the questions. Maybe a two-part for me. I guess, Rob, now that you've integrated Apogee, could you just provide your latest perspective on MA and business development appetite

Passages & reports (1)
  • Great. Thanks for taking the questions. Maybe a two-part for me. I guess, Rob, now that yo…

Speaker 5

and how ?you think about size of potential deals from here? And then

Passages & reports (3)
  • and how
  • you
  • think about size of potential deals from here? And then

Speaker 2

relatedly on obesity, a question we get a lot is: does AVI need a GLP1 to be able to compete at scale in this market? Obviously, you have the AMLIN.

Passages & reports (1)
  • relatedly on obesity, a question we get a lot is: does AVI need a GLP1 to be able to compe…

Speaker unclear

?Uh

Passages & reports (1)
  • Uh

Speaker 7

you talked about an interesting combination approach today.

Passages & reports (1)
  • you talked about an interesting combination approach today.

Speaker unclear

?Um but how do you

Passages & reports (1)
  • Um but how do you

Speaker 2

think about uh need for a GLP one? Thank ?you. Thanks, Terrence. I'll take the first question and Rupert will take the second one. So I would point ?to the Apogee deal and really the PD1 VEGF from Remogen as great examples of the BD priorities that we've been communicating for a while now. And our focus really continues to be on differentiated assets in our core areas, immunology, neuroscience, and oncology, but we're also looking to expand in obesity as well.

And I'd
say across the portfolio, it could be an early stage deal, late stage, or even on market. And again, given that our existing products and pipeline give us a clear line of sight to strong, durable growth into the 2030s, we have ample financial capacity to pursue the deals we're interested in. Now I would expect these to be more bolt-on additions versus a large transformational deal like Allargan, and that's because our business already has good breadth.

For us, it's really more about adding further depth to these areas to drive that long term growth.
?Yeah, and it's RuPaul, yes,

Passages & reports (9)
  • think about uh need for a GLP one? Thank
  • you. Thanks,
  • Terrence. I'll take the first question and Rupert will take the second one. So I would poi…
  • to
  • the Apogee deal and really the PD1 VEGF from Remogen as great examples of the BD prioritie…
  • say across the portfolio, it could be an early stage deal, late stage, or even on market. …
  • expect these to be more bolt-on additions versus a large transformational deal like Allarg…
  • Yeah,
  • and it's RuPaul, yes,

Speaker 3

we we

Passages & reports (1)
  • we we

Speaker 2

we are

Passages & reports (1)
  • we are

Speaker 3

continue to

Passages & reports (1)
  • continue to

Speaker 2

have we continue to have interest to uh build out uh obesity assets. Uh we're

Passages & reports (1)
  • have we continue to have interest to uh build out uh obesity assets. Uh we're

Speaker 3

open uh to uh anything that has a a profile that's differentiated that could match uh potentially our two nine five, especially ?uh when it comes to a co formulation. ?Uh that could be in Cretan class or or anything else. And we want to continue to drive efficacy, but very

Passages & reports (5)
  • open uh to uh anything that has a a profile that's differentiated that could match uh pote…
  • uh
  • when it comes to a co formulation.
  • Uh
  • that could be in Cretan class or or anything else. And we want to continue to drive effica…

Speaker 2

importantly tolerability, because patients still

Passages & reports (1)
  • importantly tolerability, because patients still

Speaker 3

continue to start and stop and spin off. And if we had other combo agents that continues to open the door in other indications that we already have leadership in, psoriasis, psoriatic arthritis. I already mentioned HS with an amylin, but if we ?had uh another agent, uh you could imagine us going into HS, just for context, the mean BMI of our study with Ludicisiumab

Passages & reports (3)
  • continue to start and stop and spin off. And if we had other combo agents that continues t…
  • had
  • uh another agent, uh you could imagine us going into HS, just for context, the mean BMI of…

Speaker 2

was almost

Passages & reports (1)
  • was almost

Speaker 3

34.

Passages & reports (1)
  • 34.

Speaker 2

So on average, it

Passages & reports (1)
  • So on average, it

Speaker 3

already fits a category where one could anticipate either AMLI use in the future or in Cretan use today.

Passages & reports (1)
  • already fits a category where one could anticipate either AMLI use in the future or in Cre…

Speaker 1

Thanks, Terrence. Operator, next question, please.

Passages & reports (1)
  • Thanks, Terrence. Operator, next question, please.

Speaker 0

We'll go next to Steve Scala with TD Cowan.

Passages & reports (1)
  • We'll go next to Steve Scala with TD Cowan.

Speaker 4

Thank you

Passages & reports (1)
  • Thank you

Speaker unclear

?so much.

Passages & reports (1)
  • so much.

Speaker 3

I have two questions.

Passages & reports (1)
  • I have two questions.

Speaker unclear

?Can you help us create an expectation for the Rinvoke efficacy readout in HS,

Passages & reports (1)
  • Can you help us create an expectation for the Rinvoke efficacy readout in HS,

Speaker 7

specifically on ?high score 50 placebo adjusted benefit? Should we be thinking ?about something closer to 10% or 25%?

Passages & reports (5)
  • specifically on
  • high
  • score 50 placebo adjusted benefit? Should we be thinking
  • about something closer
  • to 10% or 25%?

Speaker unclear

?So that's the first

Passages & reports (1)
  • So that's the first

Speaker 6

question. ?Second question

Passages & reports (3)
  • question.
  • Second
  • question

Speaker unclear

?is what should be our expectation for

Passages & reports (1)
  • is what should be our expectation for

Speaker 6

Botox IRA pricing, both in percentage as ?well as ?issues revolving around

Passages & reports (5)
  • Botox IRA pricing, both in percentage as
  • well
  • as
  • issues
  • revolving around

Speaker unclear

?the litigation. Presumably ABB already knows the

Passages & reports (1)
  • the litigation. Presumably ABB already knows the

Speaker 6

discount. ?So what

Passages & reports (3)
  • discount.
  • So
  • what

Speaker unclear

?can you tell us? Thank

Passages & reports (1)
  • can you tell us? Thank

Speaker 6

you so

Passages & reports (1)
  • you so

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 2

Hey Steve, it's RuPaul. For HS and Rinvoque, we

Passages & reports (1)
  • Hey Steve, it's RuPaul. For HS and Rinvoque, we

Speaker 3

still anticipate the readout

Passages & reports (1)
  • still anticipate the readout

Speaker 2

uh later this year. And as you

Passages & reports (1)
  • uh later this year. And as you

Speaker 3

mentioned, the primary endpoint is high score uh fifty. I I would say it's it's it's difficult to know what the exact delta could be. We do see that that drift in in placebo. We observed it ourselves ?with Ludicissimab. That's

Passages & reports (3)
  • mentioned, the primary endpoint is high score uh fifty. I I would say it's it's it's diffi…
  • with
  • Ludicissimab. That's

Speaker 2

probably driven by heterogeneity, larger patient populations, more sites, more countries. And it's difficult to know until

Passages & reports (1)
  • probably driven by heterogeneity, larger patient populations, more sites, more countries. …

Speaker 3

we see the phase three data. ?But the way we think about it is that high score is just one

Passages & reports (3)
  • we see the phase three data.
  • But
  • the way we think about it is that high score is just one

Speaker 2

parameter, and really the key driver, the number one symptoms that patients have and that clinicians also reiterate is pain. And what we saw with Ludi has us very encouraged because the pain started to patients had relief from pain as early as week one over the course of

Passages & reports (2)
  • parameter, and really the key driver, the number one symptoms that patients have and that …
  • as week one over the course of

Speaker 3

therapy. Quality of life is also important. Lack of flares is very important.

Passages & reports (1)
  • therapy. Quality of life is also important. Lack of flares is very important.

Speaker 2

And these

Passages & reports (1)
  • And these

Speaker 3

are the things

Passages & reports (1)
  • are the things

Speaker 2

that we would

Passages & reports (1)
  • that we would

Speaker 3

look to in the RINVOK study as well. It will come down to totality of data and what are these key drivers for patients and for clinicians. And ?what I can say is we will be capturing this evidence in the RinVOK study, just as we did in ?the Ludicisu Mab study. And what RINVOK brings is an oral, and recall that it's also coming in as a second line post other advanced therapies like other biologics.

So the setup there and the positioning is consistent with PSA, Crohn's, and
UC, where we have a biologic today, it's Sky Rizzy that goes into more frontline earlier patients, and then RinVoke comes in later. Same thing could develop here with ludicisiumab going

Passages & reports (6)
  • look to in the RINVOK study as well. It will come down to totality of data and what are th…
  • what
  • I can say is we will be capturing this evidence in the RinVOK study, just as we did in
  • the
  • Ludicisu Mab study. And what RINVOK brings is an oral, and recall that it's also coming in…
  • UC, where we have a biologic today, it's Sky Rizzy that goes into more frontline earlier p…

Speaker 2

early and then RinVoke coming in later. ?And Steve, this is Rob. I'll take your question on Botox IRA. Look, we we feel the IRA is very clear that products derived from human blood or plasma are not eligible for selection. One of Botox's three ingredients is human serum albumin, which is a protein extracted from human blood plasma. And Botox has a hundred thousand times more human serum albumin than toxin, which is why we believe Botox is not eligible for selection under the IRA.

And a federal district court just yesterday ruled in our favor. Now that ruling is subject to appeal by the government, so we'll have to wait to see if there are uh
any more proceedings. But um, you know, in the meantime, we would not expect a price to be published uh while this plays

Passages & reports (5)
  • early and then RinVoke coming in later.
  • And
  • Steve, this is Rob. I'll take your question on Botox IRA. Look, we we feel the IRA is very…
  • hundred thousand times more human serum albumin than toxin, which is why we believe Botox …
  • any more proceedings. But um, you know, in the meantime, we would not expect a price to be…

Speaker unclear

?out. Thank

Passages & reports (1)
  • out. Thank

Speaker 5

you.

Passages & reports (1)
  • you.

Speaker 1

Thanks, Steve. Operator, next question, please.

Passages & reports (1)
  • Thanks, Steve. Operator, next question, please.

Speaker 0

Our next question comes from the lung of Dave Reisinger with LeeRink Partners.

Passages & reports (1)
  • Our next question comes from the lung of Dave Reisinger with LeeRink Partners.

Speaker 3

Yes, thanks very much. And congrats on the performance

Passages & reports (1)
  • Yes, thanks very much. And congrats on the performance

Speaker unclear

?and all the updates. So I

Passages & reports (1)
  • and all the updates. So I

Speaker 3

have

Passages & reports (1)
  • have

Speaker unclear

?a question for RuPaul, please. RuPa, can you just

Passages & reports (1)
  • a question for RuPaul, please. RuPa, can you just

Speaker 7

talk ?about I and I pipeline

Passages & reports (3)
  • talk
  • about
  • I and I pipeline

Speaker 6

candidate ?trial results to watch in 2027

Passages & reports (3)
  • candidate
  • trial
  • results to watch in 2027

Speaker unclear

?after the Rinvoke

Passages & reports (1)
  • after the Rinvoke

Speaker 7

HS results in coming months. Thanks

Passages & reports (1)
  • HS results in coming months. Thanks

Speaker unclear

?very much.

Passages & reports (1)
  • very much.

Speaker 3

Hey, thanks.

Passages & reports (1)
  • Hey, thanks.

Speaker 2

It's Ruppel here. I would ?say after

Passages & reports (3)
  • It's Ruppel here. I would
  • say
  • after

Speaker 3

we see this data set, we're going to be keeping uh that's

Passages & reports (1)
  • we see this data set, we're going to be keeping uh that's

Speaker 2

the the Rinvoke HS, we're going to be keeping

Passages & reports (1)
  • the the Rinvoke HS, we're going to be keeping

Speaker 3

a close eye on the IBD combos.

Passages & reports (1)
  • a close eye on the IBD combos.

Speaker 2

And as I stated before, we'd be looking

Passages & reports (1)
  • And as I stated before, we'd be looking

Speaker unclear

?for

Passages & reports (1)
  • for

Speaker 3

um interim data to see if we can accelerate uh even even further. The other important outcome next year is Rinvoke

Passages & reports (1)
  • um interim data to see if we can accelerate uh even even further. The other important outc…

Speaker unclear

?in

Passages & reports (1)
  • in

Speaker 2

Lupus. So I would

Passages & reports (1)
  • Lupus. So I would

Speaker 3

be looking for that.

Passages & reports (1)
  • be looking for that.

Speaker 2

And then we can

Passages & reports (1)
  • And then we can

Speaker 3

anticipate

Passages & reports (1)
  • anticipate

Speaker 2

hopefully

Passages & reports (1)
  • hopefully

Speaker 3

some data out of our B cell depletion

Passages & reports (1)
  • some data out of our B cell depletion

Speaker 2

portfolio. That

Passages & reports (1)
  • portfolio. That

Speaker 3

includes a CD19 depleting antibody, the CD nineteen with an ADC, and of course our in vivo CART against C D nineteen. So we're starting to see some patients starting to enroll post the first inhuman in healthies. So that could be other very important data sets that we would see next year. Other

Passages & reports (2)
  • includes a CD19 depleting antibody, the CD nineteen with an ADC, and of course our in vivo…
  • first inhuman in healthies. So that could be other very important data sets that we would …

Speaker 2

readouts potentially are in rheumatoid arthritis, combos with lutee and psoriatic arthritis as ?well. And I would say

Passages & reports (3)
  • readouts potentially are in rheumatoid arthritis, combos with lutee and psoriatic arthriti…
  • well.
  • And I would say

Speaker 3

the not necessarily readout, but we're going to be kicking off uh plenty of studies uh post uh the apogee acquisition and you'll see the phase three star study starts with ?uh zoomy and atopic dermatitis but we're also going to be doing uh either phase two b work uh quickly I would say and then moving into phase three for uh paritis, ?uh urticaria, uh perigonodularis, and then combination work with uh the TSLP in EOE, uh asthma, COPD, sinusitis, and then imagining as those move forward, you know, eight distinct phase three programs that would be reading out in late 29 uh across the into the mid-2030s.

So quite quite a bit to keep an eye on in immunology.

Passages & reports (6)
  • the not necessarily readout, but we're going to be kicking off uh plenty of studies uh pos…
  • uh
  • zoomy and atopic dermatitis but we're also going to be doing uh either phase two b work uh…
  • uh
  • urticaria, uh perigonodularis, and then combination work with uh the TSLP in EOE, uh asthm…
  • phase three programs that would be reading out in late 29 uh across the into the mid-2030s…

Speaker 7

Great. Thanks

Passages & reports (1)
  • Great. Thanks

Speaker unclear

?so much.

Passages & reports (1)
  • so much.

Speaker 1

Thanks, Dave. Operator, next question, please.

Passages & reports (1)
  • Thanks, Dave. Operator, next question, please.

Speaker 0

We'll take our next question from Moheet Bonsel with Wells Fargo.

Passages & reports (1)
  • We'll take our next question from Moheet Bonsel with Wells Fargo.

Speaker 5

Great.

Passages & reports (1)
  • Great.

Speaker 3

Thank you very much for taking my question. And

Passages & reports (1)
  • Thank you very much for taking my question. And

Speaker unclear

?just want to touch upon

Passages & reports (1)
  • just want to touch upon

Speaker 3

Devapodon a little bit. It does seem like in the trials you ?have done longer-term data

Passages & reports (3)
  • Devapodon a little bit. It does seem like in the trials you
  • have done
  • longer-term data

Speaker unclear

?suggest that the

Passages & reports (1)
  • suggest that the

Speaker 7

drug was able to spare patients ?from Lava Dopa for a long time.

Passages & reports (3)
  • drug was able to spare patients
  • from
  • Lava Dopa for a long time.

Speaker unclear

?So would love to understand how you are thinking about

Passages & reports (1)
  • So would love to understand how you are thinking about

Speaker 7

positioning is uh ?this drug. I mean you have a five

Passages & reports (3)
  • positioning is uh
  • this
  • drug. I mean you have a five

Speaker 5

billion dollar guidance for the entire Pakistan

Passages & reports (1)
  • billion dollar guidance for the entire Pakistan

Speaker unclear

?franchise where

Passages & reports (1)
  • franchise where

Speaker 7

Devapedon

Passages & reports (1)
  • Devapedon

Speaker unclear

?is a

Passages & reports (1)
  • is a

Speaker 5

smaller

Passages & reports (1)
  • smaller

Speaker 7

part

Passages & reports (1)
  • part

Speaker 5

of ?this. But what could ?be a surprise for ?us from the upside ?point of view? ?How should ?how like what where are you positioning it and and ?what is the feedback you ?are getting so far from the

Passages & reports (17)
  • of
  • this.
  • But what could
  • be a
  • surprise for
  • us from
  • the upside
  • point of
  • view?
  • How
  • should
  • how like what
  • where are you positioning it and and
  • what is the
  • feedback you
  • are
  • getting so far from the

Speaker 7

physicians uh

Passages & reports (1)
  • physicians uh

Speaker 5

as

Passages & reports (1)
  • as

Speaker 7

you are launching this

Passages & reports (1)
  • you are launching this

Speaker 5

product? Thank

Passages & reports (1)
  • product? Thank

Speaker unclear

?you. Yeah,

Passages & reports (1)
  • you. Yeah,

Speaker 2

Mohit, it's RuPaul. I'll I'll make a few comments and then and then Jeff can speak about uh the opportunity here. Um yeah, you you you caught on to something very interesting, and that's what our experts are quite excited about. That if you're ?an early patient and you start taking Tivapidon, very, very rarely will you need, and this is I think

Passages & reports (3)
  • Mohit, it's RuPaul. I'll I'll make a few comments and then and then Jeff can speak about u…
  • an
  • early patient and you start taking Tivapidon, very, very rarely will you need, and this is…

Speaker unclear

?around eighty-five weeks or so,

Passages & reports (1)
  • around eighty-five weeks or so,

Speaker 3

that you would need to start levocarbidopa. And many clinicians are interested in keeping that in pocket as long

Passages & reports (1)
  • that you would need to start levocarbidopa. And many clinicians are interested in keeping …

Speaker 2

as possible due to the adverse events that can happen later. And we saw that same ?thing play out in a little different format on ?patients that were currently on levocarbidopa. ?You can effectively

Passages & reports (7)
  • as possible due to the adverse events that can happen later. And we saw that same
  • thing play out
  • in a little different format on
  • patients that were currently
  • on levocarbidopa.
  • You can
  • effectively

Speaker unclear

?freeze

Passages & reports (1)
  • freeze

Speaker 4

that dose with Tavapidon for the same period of time,

Passages & reports (1)
  • that dose with Tavapidon for the same period of time,

Speaker 3

approximately a year and a half. So you have the setup in those patients that are trying to optimize oral therapy, and giving Tavapidon allows them to do that very quickly, which is really nice to see because that efficacy is observed early on. And then as time goes by, because this is likely, and Jeff will talk about this,

Passages & reports (2)
  • approximately a year and a half. So you have the setup in those patients that are trying t…
  • time goes by, because this is likely, and Jeff will talk about this,

Speaker 2

where likely it will first get uh utilized, and people will then recognize that that there is ?a potential in earlier parts, and this is due

Passages & reports (3)
  • where likely it will first get uh utilized, and people will then recognize that that there…
  • a potential in
  • earlier parts, and this is due

Speaker 4

to access uh uh

Passages & reports (1)
  • to access uh uh

Speaker unclear

?uh

Passages & reports (1)
  • uh

Speaker 2

elements that Jeff can now speak ?about. Yeah, Moheed, it's it's the the the the market feedback has been quite strikingly positive so far, and it and and it is exactly that. There's two elements of it. The first is this data that RuPaul described where

Passages & reports (3)
  • elements that Jeff can now speak
  • about. Yeah,
  • Moheed, it's it's the the the the market feedback has been quite strikingly positive so fa…

Speaker 3

uh when you add it on, you essentially freeze

Passages & reports (1)
  • uh when you add it on, you essentially freeze

Speaker unclear

?any

Passages & reports (1)
  • any

Speaker 4

dose escalations in almost all the patients for 85 weeks and counting. So this this the

Passages & reports (1)
  • dose escalations in almost all the patients for 85 weeks and counting. So this this the

Speaker unclear

?the

Passages & reports (1)
  • the

Speaker 2

the the movement disorder experts and the neurologists they know that as they continue to dose up and you have to escalate levadopa carbodopa dosing it just leads to the dyskinesia

Passages & reports (1)
  • the the movement disorder experts and the neurologists they know that as they continue to …

Speaker 3

and it it's not good. So the the efficacy

Passages & reports (1)
  • and it it's not good. So the the efficacy

Speaker unclear

?from the trials has been been quite

Passages & reports (1)
  • from the trials has been been quite

Speaker 2

striking. ?And that's balanced really uh uh well with these low rates of really we call it somnolence, but the the Parkinson's experts know it's like a sleep attack. Like, you know, the patients can really get in trouble with uh uh with the sleepiness, the sedation, and these sleep attacks, and and very little to no observed impulse control disorders. And that's what really harmed the first generation of the agents that didn't

Passages & reports (4)
  • striking.
  • And
  • that's balanced really uh uh well with these low rates of really we call it somnolence, bu…
  • observed impulse control disorders. And that's what really harmed the first generation of …

Speaker unclear

?focus on D1, D five, but D two, D three. So we actually have been quite

Passages & reports (1)
  • focus on D1, D five, but D two, D three. So we actually have been quite

Speaker 2

quite surprised at how strong the profile has been reacted to. Now it's only been a matter of a few weeks. What we also see that's been surprising is patients are aware of it and they're they're pushing some of their neurologists and movement disorder experts. So ?you know in terms of upside we we know that we've missed sort of the Medicare window for 27.

You know we'd love to we'd love to be able to sort of see if we can get some early ads. That's sort of speculative at this
?point. But we are very,

Passages & reports (5)
  • quite surprised at how strong the profile has been reacted to. Now it's only been a matter…
  • you
  • know in terms of upside we we know that we've missed sort of the Medicare window for 27. Y…
  • point.
  • But we are very,

Speaker 3

very encouraged at the initial

Passages & reports (1)
  • very encouraged at the initial

Speaker 2

um ?at the initial market reaction that we're seeing. And right now, because there is no access, all we can see is sort of enrollments and people are going through medical ?acce uh acception

Passages & reports (5)
  • um
  • at
  • the initial market reaction that we're seeing. And right now, because there is no access, …
  • acce
  • uh acception

Speaker 4

processes, uh sort of the high level demand in the funnel uh has been exceeding our initial expectation. So,

Passages & reports (1)
  • processes, uh sort of the high level demand in the funnel uh has been exceeding our initia…

Speaker 3

you know, stay tuned. Uh it looks like a a very, very strong asset, uh, and

Passages & reports (1)
  • you know, stay tuned. Uh it looks like a a very, very strong asset, uh, and

Speaker unclear

?we'll just

Passages & reports (1)
  • we'll just

Speaker 2

continue to watch it and press over

Passages & reports (1)
  • continue to watch it and press over

Speaker unclear

?time. Thank you.

Passages & reports (1)
  • time. Thank you.

Speaker 1

Thanks, Mohi. We are cognizant that another peer call is starting shortly, so we just have time for one final question.

Passages & reports (1)
  • Thanks, Mohi. We are cognizant that another peer call is starting shortly, so we just have…

Speaker 0

Our last question comes from Gary Nockman with Canacord Genuity.

Passages & reports (1)
  • Our last question comes from Gary Nockman with Canacord Genuity.

Speaker 3

Thanks so much. Good morning. So with the new indications for Rinvoke and Vitiligo and Alopecia Ariata, will it be positioned as first line for both of those conditions? And I know ?you said $2 billion plus um for that in terms of the market opportunity, ?but review how big those markets are a little bit more specifically and how much you'll be increasing your presence even more with the derms after those approvals.

Passages & reports (5)
  • Thanks so much. Good morning. So with the new indications for Rinvoke and Vitiligo and Alo…
  • you said $2
  • billion plus um for that in terms of the market opportunity,
  • but
  • review how big those markets are a little bit more specifically and how much you'll be inc…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

thanks,

Passages & reports (1)
  • thanks,

Speaker 3

Gary. Great questions. And so as you know, as

Passages & reports (1)
  • Gary. Great questions. And so as you know, as

Speaker 2

I mentioned in my remarks, we we did raise uh the long term targets for both of those based on the quality of the data. So um you know alopecia

Passages & reports (1)
  • I mentioned in my remarks, we we did raise uh the long term targets for both of those base…

Speaker 3

data was substantially better than we anticipated, really transformationally. This is that you you have

Passages & reports (1)
  • data was substantially better than we anticipated, really transformationally. This is that…

Speaker 4

the ability on this ?so-called salt score in some cases to completely regrow

Passages & reports (3)
  • the ability on this
  • so-called salt
  • score in some cases to completely regrow

Speaker unclear

?hair or get ninety percent hair regrowth at

Passages & reports (1)
  • hair or get ninety percent hair regrowth at

Speaker 4

rates that we haven't seen before. So that's been positive. ?Uh Vitiligo

Passages & reports (3)
  • rates that we haven't seen before. So that's been positive.
  • Uh
  • Vitiligo

Speaker 3

data, when we look at it, is going from strength to strength. So we continue to see through seventy six weeks that we're

Passages & reports (1)
  • data, when we look at it, is going from strength to strength. So we continue to see throug…

Speaker 4

progressively improving the repigmentation. And as

Passages & reports (1)
  • progressively improving the repigmentation. And as

Speaker 3

you may recall, ?it will be the first ever systemic treatment. ?There's some topical creams, but ?it's the one for you know higher body ?surface areas. So both of these markets are very, very small right now. I mean if you look at the sales, uh you know, they're in the you ?know small hundreds of millions

Passages & reports (11)
  • you may recall,
  • it will be the
  • first ever systemic treatment.
  • There's
  • some topical creams, but
  • it's the one for
  • you know higher body
  • surface
  • areas. So both of these markets are very, very small right now. I mean if you look at the …
  • know
  • small hundreds of millions

Speaker 2

of dollars, but if you look at their prevalence, they're quite high.

Passages & reports (1)
  • of dollars, but if you look at their prevalence, they're quite high.

Speaker 3

And so, you know, that's the same way Crohn's was back in the day, and you know, ulcerative colitis, etc. So uh we see that you know we're gonna have to build the market. Uh we see that Rinvoke will have you

Passages & reports (1)
  • And so, you know, that's the same way Crohn's was back in the day, and you know, ulcerativ…

Speaker unclear

?know the most

Passages & reports (1)
  • know the most

Speaker 4

favorable data in the category for the foreseeable future. So that's that's also very uh that's

Passages & reports (1)
  • favorable data in the category for the foreseeable future. So that's that's also very uh t…

Speaker 2

also very positive. And we are anticipating with the label that we will have more, you know, now

Passages & reports (1)
  • also very positive. And we are anticipating with the label that we will have more, you kno…

Speaker 4

for moderate s to severe patients, more of a frontline type approach versus stepping through because there's really there's really nothing to to step through. Uh you sort of have these you sort of have n a naive market. And it's quite similar to what we saw with our G C A label, which is the smallest of the next one. So um you we believe that these markets can become quite

Passages & reports (2)
  • for moderate s to severe patients, more of a frontline type approach versus stepping throu…
  • the smallest of the next one. So um you we believe that these markets can become quite

Speaker 2

meaningful. We have increased our our uh our our guidance based on the quality of the data, uh, but we'll be the ones with the heavy lifting,

Passages & reports (1)
  • meaningful. We have increased our our uh our our guidance based on the quality of the data…

Speaker unclear

?and

Passages & reports (1)
  • and

Speaker 4

we plan to do that with expanding our dermatology sales forces ?around the world, and that's been underway. So

Passages & reports (3)
  • we plan to do that with expanding our dermatology sales forces
  • around the world, and
  • that's been underway. So

Speaker unclear

?we are going to

Passages & reports (1)
  • we are going to

Speaker 2

invest

Passages & reports (1)
  • invest

Speaker 4

into these indications. And certainly

Passages & reports (1)
  • into these indications. And certainly

Speaker unclear

?in the US, we would

Passages & reports (1)
  • in the US, we would

Speaker 4

also anticipate uh uh you know pretty robust consumer activation because we find that the Vitaligo and alopecia patients, you know, there's been nothing for them. So they're sort of sitting on the sideline. So that's the combination of the approaches there. We're certainly encouraged with the data and our ability to ?build those markets into the LRP.

Passages & reports (3)
  • also anticipate uh uh you know pretty robust consumer activation because we find that the …
  • build
  • those markets into the LRP.

Speaker 1

Thanks, Gary. That concludes today's conference call. If you'd like to listen to a replay of the call, please visit our website at investors.avvi.com. Thanks again for joining

Passages & reports (1)
  • Thanks, Gary. That concludes today's conference call. If you'd like to listen to a replay …

Speaker unclear

?us.

Passages & reports (1)
  • us.

Speaker 0

This concludes today's call. Thank you for your participation. You may now disconnect.

Passages & reports (1)
  • This concludes today's call. Thank you for your participation. You may now disconnect.
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

1 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 1. Unassigned words: 575. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-16T03:20:48.280Z.
Transcript version v1-ef2ca83c71542158b498 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.